Keryx Biopharmaceuticals has signed an agreement to acquire privately-held ACCESS Oncology, adding three clinical-stage cancer drug candidates to its pipeline. Keryx is to assume in the region of $7.5 million in ACCESS liabilities as a result of the acquisition and, subject to achieving specified clinical, regulatory and sales milestones, will issue a maximum of four million shares of common stock as consideration for all ACCESS shares.
Three clinical-stage compounds are included in the acquired portfolio: KRX-0401, an oral AKT-inhibitor currently in nine Phase II trials for six cancer indications; KRX-0402, a DNA repair inhibitor in multiple Phase II studies; and KRX-0403, a spindle poison expected to enter Phase II trials this year. KRX-0401 and KRX-0402 are also being studied by the National Cancer Institute under a Cooperative Research and Development Agreement.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze